Ovagen (20 mg Vial)

Ovagen is a synthetic ultrashort tripeptide (Glu-Asp-Leu; EDL) studied as a bioregulator of gastrointestinal and liver tissues. In vitro studies demonstrate that EDL increases cell proliferation and modulates aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures. No controlled human trials exist; available data are preclinical and cell-based. This educational protocol presents a once-daily subcutaneous approach with gradual titration using microgram-level dosing.

Detailed protocol below.

Dosing Schedule

Week	Daily Dose (μg)	Units (per injection) (mL)
Weeks 1–2	10 μg (0.01 mg)	0.1 units (0.001 mL)
Weeks 3–4	20 μg (0.02 mg)	0.2 units (0.002 mL)
Weeks 5–6	50 μg (0.05 mg)	0.5 units (0.005 mL)
Weeks 7–8	100 μg (0.1 mg)	1 unit (0.01 mL)
Weeks 9–16	100–150 μg (0.1–0.15 mg)	1–1.5 units (0.01–0.015 mL)

Supplies Needed

•Peptide Vials (Ovagen, 20 mg each):
•Insulin Syringes (U-100, 30-unit or 50-unit recommended):
•Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
•Alcohol Swabs: One for the vial stopper + one for the injection site each day.

References

MDPI International Journal of Molecular Sciences
Transport of biologically active ultrashort peptides using POT and LAT carriers
View source
PubMed — Advances in Gerontology
Advances in Gerontology**
View source
Nature — Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy**
View source
Sigma-Aldrich
Peptide Handling and Storage Guide (aliquoting, freeze–thaw, labeling)
View source
Bachem
Handling and Storage Guidelines for Peptides (temperature, stability)
View source
PubMed — Biochemistry
Biochemistry**
View source
PubMed — Biochemistry
Biochemistry**
View source
NCBI Bookshelf — WHO
WHO**
View source
CDC
Vaccine administration: subcutaneous route (angle/site guidance)
View source
CDC (Subcut Injection PDF)
Technique diagram and site guidance for subcutaneous injections
View source

Educational content adapted from peptidedosages.com. Not medical advice.